Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

News   Jun 02, 2009

 
Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
 
 
 

RELATED ARTICLES

New Speakers from Roche and Imperial College London Announced for SMi’s ADMET Event

News

SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.

READ MORE

Cell Technology Used to Treat Osteochondral Knee Defect

News

Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.

READ MORE

Compound as Effective as FDA-Approved Drugs Against Life-Threatening Infections

News

Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy